8-K/A: Tevogen Bio Secures $6 Million Investment Through Amended Preferred Stock Agreement

Tevogen Bio Holdings Inc. amended a securities purchase agreement, securing $6 million through the sale of Series A-1 Preferred Stock.

Summary

• Tevogen Bio amended a previous agreement to sell Series A-1 Preferred Stock to an investor for $6 million.
• The Series A-1 Preferred Stock is convertible into 600,000 shares of common stock.
• The preferred stock has a call option for the company if the common stock price exceeds $5.00 and a resale registration is in place.
• The Series A-1 Preferred Stock is non-voting, has no mandatory redemption, and pays a 5% cumulative annual dividend, increasing by 2% each year to a maximum of 15%.
• The company cannot amend its charter or bylaws in a way that is adverse to the Series A-1 Preferred Stock without the consent of 50.1% of the holders.
• The Series A-1 Preferred Stock ranks senior to common stock and Series B Preferred Stock in terms of dividends and liquidation rights.
• The original issue price of the Series A-1 Preferred Stock is $10,000 per share.
• The Series A-1 Preferred Stock holders will also participate in any regular or special dividends paid to common stock holders on an as-converted basis.
• The Series A-1 Preferred Stock has no stated maturity and is not subject to any sinking fund.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the successful capital raise, but there are some potential risks and restrictions associated with the terms of the preferred stock.

Positives

• The company successfully raised $6 million in funding.
• The terms of the Series A-1 Preferred Stock include a call option that could benefit the company if the stock price increases.
• The Series A-1 Preferred Stock has a cumulative dividend, which could be attractive to investors.
• The Series A-1 Preferred Stock ranks senior to common stock and Series B Preferred Stock in terms of dividends and liquidation rights, providing a level of security for the investor.

Negatives

• The Series A-1 Preferred Stock is non-voting, which could limit the investor's influence on company decisions.
• The company is restricted from amending its charter or bylaws in a way that is adverse to the Series A-1 Preferred Stock without the consent of 50.1% of the holders.
• The dividend rate increases annually, potentially increasing the cost of capital for the company over time.

Risks

• The company's ability to call the Series A-1 Preferred Stock is contingent on the common stock price exceeding $5.00 and a resale registration being in place.
• The increasing dividend rate could become a financial burden if the company's performance does not improve.
• The investor has significant influence over changes to the company's charter and bylaws.

Future Outlook

The company has secured additional funding, which may support future growth and operations. The call option on the preferred stock could provide future flexibility.

Industry Context

This type of financing is common for biotech companies seeking to fund research and development. The terms of the preferred stock are fairly standard for this type of investment.

Comparison to Industry Standards

• The use of preferred stock with a convertible feature is a common method for biotech companies to raise capital, similar to companies like XOMA Corporation and Agenus Inc.
• The dividend rate of 5% increasing to a maximum of 15% is within the typical range for preferred stock in the biotech sector, comparable to rates seen in similar financings by companies like Celldex Therapeutics.
• The call option based on a stock price threshold is a common feature to protect the company from excessive dilution, similar to terms seen in financings by companies like BioMarin Pharmaceutical.

Corporate Governance

Related Party Transactions

• The investor is an entity associated with Dr. Manmohan Patel, an existing investor and beneficial owner of more than 5% of the company's common stock.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• The company's financial stability is improved with the additional funding.
• The terms of the preferred stock may impact the company's future financial flexibility.

Next Steps

• The company will continue to operate with the newly secured funding.
• The company will monitor the common stock price to determine if the call option on the preferred stock can be exercised.
• The company will need to manage the increasing dividend rate on the preferred stock.

Key Dates

Keywords

Preferred Stock, Securities Purchase Agreement, Capital Raise, Investment, Convertible Stock, Dividends, Tevogen Bio, Series A-1 Preferred Stock